A spirocyclic tert-amino acid compound and its preparation method and application

Through the structural transformation of teracic acid skeleton compounds, spirocyclic teracic compounds were developed, and the VDAC1 function was inhibited by the structure of pyrrolidin-2,4-dione or pyrroline-2-one, which solved the teracic acid skeleton compounds. The problem of insufficient anti-cancer activity has achieved effective inhibition of cancer cells, especially the significant inhibitory effect of compounds 9d and 9b on H1299, RKO and MCF-7 cells.

CN118164897BActive Publication Date: 2024-11-15NANKAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410270889.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-11
Publication Date
2024-11-15
Estimated Expiration
2044-03-11

AI Technical Summary

Technical Problem

Teramine skeleton compounds are not ideal in anti-cancer activity, and the prior art is difficult to effectively modify their structures to improve biological activity.

Method used

Develop a spirocyclic teracic acid compound that uses pyrrolidin-2,4-dione or pyrroline-2-one structures to inhibit VDAC1 function and interfere with cytoplasmic and mitochondrial intermembrane substances through specific chemical structural modification and synthesis methods. Exchange, and then have anti-cancer biological functions.

Benefits of technology

The spirocyclic teracic acid compounds provided show significant inhibitory effects on human cell lung cancer, human colon adenocarcinoma and human breast cancer cells. The effects of Compound 9d and Compound 9b are particularly outstanding and are suitable for the application of anti-cancer drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118164897B_ABST
    Figure CN118164897B_ABST
Patent Text Reader

Abstract

The present invention provides a spirocyclic tertamine compound and a preparation method and application thereof, belonging to the field of drug molecule technology. The results of the examples show that the inhibitory effect of the compounds of formula II (8a-9e) provided by the present invention on H1299, RKO and MCF-7 cancer cells is stronger than that of the compounds of formula I (4a-6a), and the effects of compounds 9d and 9b are the best.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug molecules, and in particular to a spirocyclic tert-amino acid compound and a preparation method and application thereof. Background Art

[0002] Tetramine skeleton compounds are a class of nitrogen-containing heterocyclic compounds containing pyrrolidine-2,4-dione or pyrroline-2-one structures. Natural products containing tetramine skeletons can be mainly isolated from a variety of marine products and terrestrial organisms such as sponges, cyanobacteria, bacteria and fungi. They often have a variety of biological activities, such as antioxidant, anti-tumor, herbicidal and bactericidal activities. The previous inventors took the lead in developing a series of preparation methods and applications of tetramine derivatives (Chinese patent application: CN202110065664.6 Preparation method of tricholoma oxadione acid and its derivatives; Chinese patent application: CN202111029347.5 5-n-propyl-4-hydroxypyrrole-2-one derivatives and their preparation methods and applications; Chinese patent application: CN202110646053.0 Tetramine derivatives and their preparation methods and applications). Biological activity studies have shown that tert-amino acid compounds have different herbicidal activities against agricultural weeds such as barnyard grass, goosegrass, and purslane, but their anti-cancer activity is not ideal. Therefore, how to transform and develop the structure of tert-amino acid skeleton compounds so that they can be better used in pharmaceutical production and solve the current problems of single biological activity and unsatisfactory activity of tert-amino acid skeleton compounds has become a technical problem that needs to be solved in this field. Summary of the invention

[0003] The purpose of the present invention is to provide a spirocyclic tert-amino acid compound and a preparation method and application thereof. The spirocyclic tert-amino acid compound provided by the present invention has anti-cancer biological function.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The present invention provides a spirocyclic tert-amino acid compound having a chemical structure shown in Formula I or Formula II:

[0006]

[0007] In the formula I, R1 is any one of the following groups:

[0008]

[0009] In the formula II, R2 is any one of the following groups:

[0010]

[0011] Preferably, in the formula I, n is 2 or 3.

[0012] Preferably, in the formula II, n is 1 or 3.

[0013] Preferably, the spirocyclic tert-amino acid compound represented by formula I is any one of the following:

[0014] Preferably, the spirocyclic tert-amino acid compound represented by formula II is any one of the following:

[0015]

[0016] The present invention also provides a method for preparing the spirocyclic tert-amino acid compound described in the above technical scheme, comprising the following steps:

[0017] (1) mixing cycloisopropyl malonate, acyl chloride, a first catalyst and a first solvent to perform a nucleophilic substitution reaction to obtain a first intermediate;

[0018] (2) mixing the first intermediate obtained in step (1), the second solvent, the second catalyst and 1-aminocyclobutanecarboxylic acid methyl ester / 1-aminocyclopentanecarboxylic acid methyl ester, and performing a first amidation reaction to obtain a second intermediate;

[0019] (3) The second intermediate obtained in step (2), the third solvent and the third catalyst are mixed to carry out a first Diekmann condensation reaction to obtain the spirocyclic tert-amino acid compound of formula I.

[0020] The present invention also provides a method for preparing the spirocyclic tert-amino acid compound described in the above technical scheme, comprising the following steps:

[0021] 1) mixing 1-aminocycloalkanecarboxylic acid methyl ester, a fourth solvent, a fourth catalyst and 2,4-dichlorophenylacetic acid, and performing a second amidation reaction to obtain a third intermediate;

[0022] 2) mixing the third intermediate obtained in step 1), the fifth solvent and the fifth catalyst, and performing a second Diekmann condensation reaction to obtain the spirocyclic tert-amino acid compound of formula II;

[0023] Alternatively, the third intermediate obtained in step 1), the fifth solvent and the fifth catalyst are mixed to carry out a second Diekmann condensation reaction to obtain a fourth intermediate, and the fourth intermediate, the acid, the sixth catalyst and the sixth solvent are mixed to carry out an esterification reaction to obtain the spirocyclic tertamine compound described in formula II; the acid is benzoic acid, 4-trifluoromethylbenzoic acid, n-valeric acid, isovaleric acid or 3,4-difluorobenzoic acid.

[0024] Preferably, the temperature of the esterification reaction in step 2) is 10 to 30° C., and the time of the esterification reaction is 8 to 10 hours.

[0025] The present invention also provides the use of the spirocyclic tert-amino acid compound described in the above technical scheme or the spirocyclic tert-amino acid compound prepared by the preparation method described in the above technical scheme in anticancer drugs.

[0026] Preferably, the cancer cells in the anticancer drug include human large cell lung cancer cells, human colon adenocarcinoma cells and human breast cancer cells.

[0027] The present invention provides a spirocyclic tertiary amino acid compound having a chemical structure shown in Formula I or Formula II. The present invention uses a tertiary amino acid skeleton compound containing a pyrrolidine-2,4-dione or pyrroline-2-one structure, wherein the pyrrolidine-2,4-dione or pyrroline-2-one structure can inhibit the VDAC1 function, interfere with the exchange of substances between the cytoplasm and the mitochondrial membrane, and disrupt the oxidative phosphorylation of alanine A and B, and VDAC1 plays a key role in mitochondrial permeability transition and mitochondrial-mediated apoptosis, and is one of the targets for cancer cell treatment. Since VDAC1 has a barrel structure (19-chain β-barrel folds), based on the analogy of "lock and key", it may have an indestructible pocket, which can be stably combined with the tertiary amino acid skeleton, so that the spirocyclic tertiary amino acid compound has an anti-cancer biological function.

[0028] The results of the examples show that the compounds of formula II (8a-9e) provided by the present invention have stronger inhibitory effects on H1299, RKO and MCF-7 cancer cells than the compounds of formula I (4a-6a), and compounds 9d and 9b have the best effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 is the hydrogen spectrum structure diagram of compound 9b;

[0030] Figure 2 This is the hydrogen spectrum structure diagram of compound 9d. DETAILED DESCRIPTION

[0031] The present invention provides a spirocyclic tert-amino acid compound having a chemical structure shown in Formula I or Formula II:

[0032]

[0033] In the formula I, R1 is any one of the following groups:

[0034]

[0035] In the formula II, R2 is any one of the following groups:

[0036]

[0037] In one technical solution of the present invention, the spirocyclic tert-amino acid compound has a chemical structure shown in Formula I:

[0038]

[0039] In the present invention, in the formula I, R1 is any one of the following groups:

[0040] Preferred is 4-methoxyphenyl.

[0041] In the present invention, in the formula I, n is preferably 2 or 3, more preferably 2.

[0042] In the present invention, the spirocyclic tert-amino acid compound represented by formula I is preferably any one of the following:

[0043]

[0044] In another technical solution of the present invention, the spirocyclic tert-amino acid compound has a chemical structure shown in Formula II:

[0045]

[0046] In the present invention, in the formula II, R2 is any one of the following groups:

[0047] Preferred is a trifluoromethylbenzoyl group or a 3,4-difluorobenzoyl group.

[0048] In the present invention, in the formula II, n is preferably 1 or 3, more preferably 3.

[0049] In the present invention, the spirocyclic tert-amino acid compound represented by formula II is preferably any one of the following:

[0050]

[0051] The present invention also provides a method for preparing the spirocyclic tert-amino acid compound described in the above technical scheme, comprising the following steps:

[0052] (1) mixing cycloisopropyl malonate, acyl chloride, a first catalyst and a first solvent to perform a nucleophilic substitution reaction to obtain a first intermediate;

[0053] (2) mixing the first intermediate obtained in step (1), the second solvent, the second catalyst and 1-aminocyclobutanecarboxylic acid methyl ester / 1-aminocyclopentanecarboxylic acid methyl ester, and performing a first amidation reaction to obtain a second intermediate;

[0054] (3) The second intermediate obtained in step (2), the third solvent and the third catalyst are mixed to carry out a first Diekmann condensation reaction to obtain the spirocyclic tert-amino acid compound of formula I.

[0055] The present invention has no particular limitation on the sources of the raw materials, and commercially available products known to those skilled in the art may be used.

[0056] The invention mixes cycloisopropyl malonate, acyl chloride, a first catalyst and a first solvent, and performs a nucleophilic substitution reaction to obtain a first intermediate.

[0057] In the present invention, the acyl chloride is preferably R1-COCl; the R1 is preferably the same as R1 in the aforementioned formula I, which will not be repeated here.

[0058] In the present invention, the first catalyst is preferably 4-dimethylaminopyridine.

[0059] In the present invention, the first solvent is preferably dichloromethane or pyridine.

[0060] In the present invention, the molar ratio of the cycloisopropylidene malonate to the acyl chloride is preferably 1:(1-1.5); the molar ratio of the cycloisopropylidene malonate to the first catalyst is preferably 1:(2-3).

[0061] In the present invention, the mixture of cycloisopropyl malonate, acyl chloride, the first catalyst and the first solvent is preferably:

[0062] 1. Mixing cycloisopropyl malonate, a first catalyst and a portion of a first solvent to obtain a first mixed solution;

[0063] 2. Mixing the acyl chloride and the remaining first solvent to obtain a second mixed solution;

[0064] 3. Add the second mixed solution obtained in step 2 dropwise to the first mixed solution obtained in step 1;

[0065] There is no order of precedence for steps 1 and 2.

[0066] In the present invention, cycloisopropyl malonate, the first catalyst and part of the first solvent are preferably mixed to obtain a first mixed solution.

[0067] The present invention has no particular limitation on the amount of the first solvent, as long as the raw materials can be dissolved.

[0068] The present invention has no special limitation on the operation of mixing the cycloisopropyl malonate, the first catalyst and part of the first solvent, and the technical scheme for preparing the mixed material well known to those skilled in the art can be adopted.

[0069] In the present invention, the mixing of the cycloisopropyl malonate, the first catalyst and part of the first solvent is preferably carried out in an ice-water bath; the temperature of the ice-water bath is preferably 0-5°C.

[0070] In the present invention, the acyl chloride and the remaining first solvent are preferably mixed to obtain a second mixed solution.

[0071] The present invention has no particular limitation on the amount of the remaining first solvent, as long as the raw materials can be dissolved.

[0072] The present invention has no special limitation on the operation of mixing the acyl chloride and the remaining first solvent, and the technical scheme for preparing the mixed material well known to those skilled in the art can be adopted.

[0073] After obtaining the first mixed solution and the second mixed solution, the present invention preferably drops the second mixed solution into the first mixed solution.

[0074] In the present invention, the dripping rate is preferably 0.33 mL / min. The present invention can avoid excessively fast dripping rate leading to violent heat release in the reaction by controlling the dripping rate.

[0075] In the present invention, the dropwise addition is preferably carried out under nitrogen protection. The use of nitrogen protection in the present invention can avoid hydrolysis of the acyl chloride.

[0076] In the present invention, the dropping is preferably carried out in an ice-water bath; the temperature of the ice-water bath is preferably 0-5°C.

[0077] After the dropwise addition is completed, the solution obtained by the dropwise addition is preferably stirred. The stirring operation is not particularly limited in the present invention, and an operation well known to those skilled in the art can be adopted. The stirring time is not particularly limited in the present invention, as long as the raw materials are uniformly mixed.

[0078] In the present invention, the temperature of the nucleophilic substitution reaction is preferably 10 to 30° C.; the time of the nucleophilic substitution reaction is preferably 8 to 12 hours.

[0079] In the present invention, the nucleophilic substitution reaction is preferably carried out under stirring conditions. The present invention has no particular limitation on the stirring operation, and any operation well known to those skilled in the art may be used.

[0080] After the nucleophilic substitution reaction is completed, the present invention preferably sequentially washes, dries, rotary evaporates, recrystallizes and filters the organic phase obtained by the nucleophilic substitution reaction to obtain a first intermediate.

[0081] In the present invention, the washing is preferably carried out in sequence using hydrochloric acid, saturated saline and water. The present invention has no particular limitation on the washing operation, and the operation well known to those skilled in the art can be used.

[0082] The present invention has no particular limitation on the drying and rotary evaporation operations, and operations well known to those skilled in the art may be used.

[0083] In the present invention, the extractant used in the recrystallization is preferably diethyl ether; the temperature of the diethyl ether is preferably 20-30°C.

[0084] The present invention has no particular limitation on the filtration operation, and any operation well known to those skilled in the art may be used.

[0085] After obtaining the first intermediate, the present invention mixes the first intermediate, the second solvent, the second catalyst and 1-aminocyclobutanecarboxylic acid methyl ester / 1-aminocyclopentanecarboxylic acid methyl ester to carry out a first amidation reaction to obtain the second intermediate.

[0086] In the present invention, the molar ratio of the first intermediate to methyl 1-aminocyclobutanecarboxylate / methyl 1-aminocyclopentanecarboxylate is preferably 1:(1-1.3).

[0087] In the present invention, the second solvent is preferably 1,4-dioxane or tetrahydrofuran.

[0088] The present invention has no particular limitation on the amount of the second solvent, as long as the raw materials can be dissolved.

[0089] In the present invention, the second catalyst is preferably triethylamine; the molar ratio of the second catalyst to methyl 1-aminocyclobutanecarboxylate / methyl 1-aminocyclopentanecarboxylate is preferably 1:(1-1.5).

[0090] In the present invention, the mixing of the first intermediate, the second solvent, the second catalyst and 1-aminocyclobutanecarboxylic acid methyl ester / 1-aminocyclopentanecarboxylic acid methyl ester is preferably to mix 1-aminocyclobutanecarboxylic acid methyl ester / 1-aminocyclopentanecarboxylic acid methyl ester with the second solvent, the second catalyst and the first intermediate in sequence; the mixing is preferably carried out in an ice-water bath and under stirring conditions; the temperature of the ice-water bath is preferably 0 to 5°C. The present invention has no special limitation on the stirring operation, and the operation well known to those skilled in the art can be adopted. The present invention adopts ice bath stirring to reduce the system temperature and avoid violent reaction when the first intermediate is added.

[0091] In the present invention, the temperature of the first amidation reaction is preferably 70-110°C; when the second solvent is 1,4-dioxane, the temperature of the first amidation reaction is preferably 90-110°C; when the second solvent is tetrahydrofuran, the temperature of the first amidation reaction is preferably 70-90°C; and the time of the first amidation reaction is preferably 6-8h.

[0092] After the first amidation reaction is completed, the present invention preferably sequentially performs vacuum concentration, dissolution, organic phase washing, drying, filtration, rotary evaporation and column chromatography purification on the product obtained by the first amidation reaction to obtain a second intermediate.

[0093] The present invention has no particular limitation on the operations of vacuum concentration, dissolution, organic phase washing, drying, filtration, rotary evaporation and column chromatography purification, and operations well known to those skilled in the art may be used.

[0094] After obtaining the second intermediate, the present invention mixes the second intermediate, the third solvent and the third catalyst to carry out a first Diekmann condensation reaction to obtain the spirocyclic tertamine compound of formula I.

[0095] In the present invention, the third solvent is preferably methanol or ethanol. The present invention has no particular limitation on the amount of the third solvent, as long as the raw materials can be dissolved.

[0096] In the present invention, the third catalyst is preferably sodium methoxide solution or sodium ethoxide; the molar ratio of the sodium methoxide to the second intermediate is preferably (1-3):1; the molar ratio of the sodium ethoxide to the second intermediate is preferably (1-3):1.

[0097] In the present invention, the solvent of the sodium methoxide solution is preferably methanol. The present invention has no particular limitation on the concentration of the sodium methoxide solution, as long as the amount of the substance with the second intermediate is within the above range.

[0098] In the present invention, when the third catalyst is sodium methoxide solution, the third solvent is preferably methanol; when the third catalyst is sodium ethoxide, the third solvent is preferably ethanol.

[0099] The present invention has no special limitation on the operation of mixing the second intermediate, the third solvent and the third catalyst, and the technical scheme for preparing the mixed material well known to those skilled in the art can be adopted.

[0100] In the present invention, the temperature of the first Diekmann condensation reaction is preferably 75 to 95° C.; the time of the first Diekmann condensation reaction is preferably 6 to 8 hours.

[0101] In the present invention, when the third solvent is methanol, the temperature of the first Diekmann condensation reaction is preferably 75-90°C; when the third solvent is ethanol, the temperature of the first Diekmann condensation reaction is preferably 80-95°C.

[0102] After the first Diekmann condensation reaction is completed, the present invention preferably performs rotary evaporation, dissolution, extraction, drying, filtration and evaporation on the product obtained by the first Diekmann condensation reaction in sequence to obtain the spirocyclic tertiary amino acid compound described in Formula I.

[0103] The present invention has no particular limitation on the operations of rotary evaporation, dissolving, extracting, drying, filtering and evaporating, and operations well known to those skilled in the art may be adopted.

[0104] In the present invention, when 1-aminocyclobutanecarboxylic acid methyl ester is used, the spirocyclic tert-amine compounds described in 4a to 4i are preferably obtained; when 1-aminocyclopentanecarboxylic acid methyl ester is used, the spirocyclic tert-amine compound described in 6a is preferably obtained.

[0105] The present invention also provides a method for preparing the spirocyclic tert-amino acid compound described in the above technical scheme, comprising the following steps:

[0106] 1) mixing 1-aminocycloalkanecarboxylic acid methyl ester, a fourth solvent, a fourth catalyst and 2,4-dichlorophenylacetic acid, and performing a second amidation reaction to obtain a third intermediate;

[0107] 2) mixing the third intermediate obtained in step 1), the fifth solvent and the fifth catalyst, and performing a second Diekmann condensation reaction to obtain the spirocyclic tert-amino acid compound of formula II;

[0108] Alternatively, the third intermediate obtained in step 1), the fifth solvent and the fifth catalyst are mixed to carry out a second Diekmann condensation reaction to obtain a fourth intermediate, and the fourth intermediate, the acid, the sixth catalyst and the sixth solvent are mixed to carry out an esterification reaction to obtain the spirocyclic tertamine compound described in formula II; the acid is benzoic acid, 4-trifluoromethylbenzoic acid, n-valeric acid, isovaleric acid or 3,4-difluorobenzoic acid.

[0109] The present invention has no particular limitation on the sources of the raw materials, and commercially available products known to those skilled in the art may be used.

[0110] The invention mixes 1-aminocycloalkane carboxylic acid methyl ester, a fourth solvent, a fourth catalyst and 2,4-dichlorophenylacetic acid, and performs a second amidation reaction to obtain a third intermediate.

[0111] In the present invention, the 1-aminocycloalkanecarboxylic acid methyl ester is preferably 1-aminocyclopropanecarboxylic acid methyl ester or 1-aminocyclopentanecarboxylic acid methyl ester.

[0112] In the present invention, the fourth solvent is preferably dichloromethane. The present invention has no particular limitation on the amount of the fourth solvent, as long as it can dissolve the raw materials.

[0113] In the present invention, the fourth catalyst is preferably at least one of 4-dimethylaminopyridine, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, dicyclohexylcarbodiimide and diisopropylcarbodiimide, more preferably 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; the molar ratio of the 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is preferably 1:1.

[0114] In the present invention, the molar ratio of the fourth catalyst to methyl 1-aminocycloalkanecarboxylate is preferably (3-4):1; the molar ratio of methyl 1-aminocycloalkanecarboxylate to 2,4-dichlorophenylacetic acid is preferably 1:(1.5-2).

[0115] The present invention has no particular limitation on the operation of mixing the 1-aminocycloalkanecarboxylic acid methyl ester, the fourth solvent, the fourth catalyst and the 2,4-dichlorophenylacetic acid, and a technical scheme for preparing the mixed material well known to those skilled in the art can be used.

[0116] In the present invention, the temperature of the second amidation reaction is preferably 10 to 30° C.; the time of the second amidation reaction is preferably 10 to 12 hours; and the second amidation reaction is preferably carried out under stirring conditions. The present invention has no particular limitation on the stirring operation, and the operation familiar to those skilled in the art can be used.

[0117] After the second amidation reaction is completed, the present invention preferably sequentially performs suction filtration, washing, drying, filtration, rotary evaporation and column chromatography purification on the product obtained by the second amidation reaction to obtain a third intermediate.

[0118] The present invention has no particular limitation on the operations of suction filtration, washing, drying, filtering, rotary evaporation and purification by column chromatography, and operations well known to those skilled in the art may be used.

[0119] In one technical solution of the present invention, after obtaining the third intermediate, the third intermediate, the fifth solvent and the fifth catalyst are mixed to carry out a second Diekmann condensation reaction to obtain the spirocyclic tertiary amino acid compound of formula II.

[0120] In the present invention, the fifth solvent is preferably methanol or ethanol. The present invention has no particular limitation on the amount of the fifth solvent, as long as the raw materials can be dissolved.

[0121] In the present invention, the fifth catalyst is preferably sodium methoxide solution or sodium ethoxide; the molar ratio of the sodium methoxide to the third intermediate is preferably (1-3):1; the molar ratio of the sodium ethoxide to the third intermediate is preferably (1-3):1.

[0122] In the present invention, the solvent of the sodium methoxide solution is preferably methanol. The present invention has no particular limitation on the concentration of the sodium methoxide solution, as long as the amount of the substance with the third intermediate is within the above range.

[0123] In the present invention, when the fifth catalyst is sodium methoxide solution, the fifth solvent is preferably methanol; when the fifth catalyst is sodium ethoxide, the fifth solvent is preferably ethanol.

[0124] The present invention has no special limitation on the operation of mixing the third intermediate, the fifth solvent and the fifth catalyst, and the technical scheme for preparing the mixed material well known to those skilled in the art can be adopted.

[0125] In the present invention, the temperature of the second Diekmann condensation reaction is preferably 75 to 95° C.; the time of the second Diekmann condensation reaction is preferably 6 to 8 hours.

[0126] In the present invention, when the fifth solvent is methanol, the temperature of the second Diekmann condensation reaction is preferably 75-90°C; when the fifth solvent is ethanol, the temperature of the second Diekmann condensation reaction is preferably 80-95°C.

[0127] After the second Diekmann condensation reaction is completed, the present invention preferably performs rotary evaporation, dissolution, extraction, drying, filtration and evaporation on the product obtained by the second Diekmann condensation reaction in sequence to obtain the spirocyclic tertiary amino acid compound described in Formula II.

[0128] The present invention has no particular limitation on the operations of rotary evaporation, dissolving, extracting, drying, filtering and evaporating, and operations well known to those skilled in the art may be adopted.

[0129] In the present invention, the spirocyclic tert-amino acid compound described in Formula II is preferably 8a or 8b.

[0130] In another technical solution of the present invention, after obtaining the third intermediate, the third intermediate, the fifth solvent and the fifth catalyst are mixed to carry out a second Diekmann condensation reaction to obtain a fourth intermediate, and the fourth intermediate, the acid, the sixth catalyst and the sixth solvent are mixed to carry out an esterification reaction to obtain the spirocyclic tertamine compound described in formula II.

[0131] In the present invention, the operation of mixing the third intermediate, the fifth solvent and the fifth catalyst to carry out the second Diekmann condensation reaction to obtain the fourth intermediate is preferably the same as the above operation, which will not be repeated here.

[0132] In the present invention, the acid is benzoic acid, 4-trifluoromethylbenzoic acid, n-valeric acid, isovaleric acid or 3,4-difluorobenzoic acid.

[0133] In the present invention, the sixth catalyst is preferably at least one of 4-dimethylaminopyridine, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, dicyclohexylcarbodiimide and diisopropylcarbodiimide, more preferably 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; the molar ratio of the 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is preferably 1:1.

[0134] In the present invention, the molar ratio of the sixth catalyst to the fourth intermediate is preferably (3-4):1; the molar ratio of the fourth intermediate to the acid is preferably 1:(1.0-1.5).

[0135] In the present invention, the sixth solvent is preferably dichloromethane. The present invention has no particular limitation on the amount of the sixth solvent, as long as the raw materials can be dissolved.

[0136] The present invention has no special limitation on the operation of mixing the fourth intermediate, the acid, the sixth catalyst and the sixth solvent, and the technical scheme for preparing the mixed material well known to those skilled in the art can be adopted.

[0137] In the present invention, the temperature of the esterification reaction is preferably 10 to 30° C.; the time of the esterification reaction is preferably 8 to 10 hours.

[0138] After the esterification reaction is completed, the product obtained by the esterification reaction is preferably filtered, diluted, washed, dried, concentrated and purified by column chromatography in sequence to obtain the spirocyclic tertiary amino acid compound described in Formula II.

[0139] The present invention has no particular limitation on the filtering operation, and any operation well known to those skilled in the art may be used.

[0140] In the present invention, the diluent used for the dilution is preferably dichloromethane. The present invention has no particular limitation on the amount of dichloromethane used, as long as the filtrate obtained by filtration is diluted.

[0141] In the present invention, the detergents used for the washing are preferably 5% NaHCO3 solution, 1 mol / L hydrochloric acid and pure water in sequence.

[0142] The present invention has no special limitation on the amount of the detergent and the number of washing times, which can be determined according to common sense.

[0143] The present invention has no particular limitation on the operations of drying, concentrating and purifying by column chromatography, and operations well known to those skilled in the art may be used.

[0144] In the present invention, the spirocyclic tert-amino acid compound described in Formula II is preferably 9a to 9e.

[0145] The present invention also provides the use of the spirocyclic tert-amino acid compound described in the above technical scheme or the spirocyclic tert-amino acid compound prepared by the preparation method described in the above technical scheme in anticancer drugs.

[0146] In the present invention, the cancer cells in the anticancer drug preferably include human large cell lung cancer (LCC) cells, human colon adenocarcinoma cells and human breast cancer cells.

[0147] In the present invention, compound 9a, compound 9c, compound 9d and compound 9e have the strongest inhibitory effect on human large cell lung cancer (LCC) cells, and compound 9a, compound 9c and compound 9d have the strongest inhibitory effect on human colon adenocarcinoma cells.

[0148] In the present invention, compound 9d and compound 9b have better effects on human large cell lung cancer (LCC) cells, human colon adenocarcinoma cells and human breast cancer cells.

[0149] The spirocyclic tert-amino acid skeleton compound of the present invention is obtained by molecularly modifying the tenuisporic acid. Experimental studies have shown that it has good inhibitory effects on human large cell lung cancer (LCC) cells, human colon adenocarcinoma cells, and human breast cancer cells at 24 hours, especially compound 9d and compound 9b. The raw materials of the spirocyclic tert-amino acid skeleton compound of the present invention are cheap and easy to obtain, the synthesis method is simple and efficient, suitable for industrial production, and has great application potential.

[0150] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0151] The instruments, reagents, and materials involved in the following embodiments, unless otherwise specified, are conventional instruments, reagents, and materials already available in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following embodiments, unless otherwise specified, are conventional experimental methods and detection methods already available in the prior art. For process parameters not specifically noted, conventional techniques can be used.

[0152] Terminology used: "TLC" refers to TLC thin layer chromatography technique.

[0153] Example 1

[0154] Preparation of the compound shown in formula I:

[0155] (i) When n=2, the compound represented by Formula I is Compound 4a, Compound 4b, Compound 4c, Compound 4d, Compound 4e, Compound 4f, Compound 4g, Compound 4h and Compound 4i, and the following preparation methods are used to prepare Compounds 4a to 4i respectively; the steps are as follows:

[0156] (1) Synthesis of compounds 2a to 2i

[0157] In a reaction flask, add 10 mmol of cycloisopropyl malonate and 20 mmol of 4-dimethylaminopyridine to 50 mL of dichloromethane in an ice-water bath; dissolve 10 mmol of acyl chloride R1-COCl (R1 is Ia-Ii) 1a-1i in 10 mL of dichloromethane respectively, and slowly add dropwise to the above-mentioned cycloisopropyl malonate solution under nitrogen protection within 0.5 h at a dropping rate of 0.33 mL / min. Stir in an ice-water bath at 0°C for 1 h. After h, the ice-water bath was removed, and the temperature was gradually restored to room temperature of 25°C. The reaction was continued to stir for 10 h, and the TLC spot plate detection was followed. After the raw material reaction was complete, the organic phase was washed with 1 mol / L hydrochloric acid (washed 3 times, 60 mL each time), 80 mL of saturated brine and 80 mL of water, respectively, and the organic phase was collected, dried, and then rotary evaporated at room temperature using a rotary evaporator to obtain a crude product, which was then recrystallized using 25°C hot ether and filtered to obtain compounds 2a~2i.

[0158] Compound 2a: white solid, yield 82%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.40 (s, 1H), 7.18 (d, J=12.5Hz, 1H), 6.85 (d, J=8.8Hz, 1H), 5.50 (s, 2H), 1.77 (s, 6H).

[0159] Compound 2b: white solid, yield 83%. The characterization data of the compound are as follows: 1 H NMR (600 MHz, dmso) δ 7.72 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 8.2 Hz, 2H), 1.67 (s, 6H).

[0160] Compound 2c: white solid, yield 77%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.54-7.47 (m, 2H), 7.07 (t, J=7.5Hz, 1H), 6.93 (d, J=8.4Hz, 1H), 3.81 (s, 3H), 1.82 (s, 6H).

[0161] Compound 2d: white solid, yield 79%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.70 (d, J=8.9Hz, 2H), 7.40 (t, J=7.6Hz, 2H), 7.21 (t, J=7.5Hz, 1H), 7.10 (d, J=6.6Hz, 2H), 6.98 (d, J=9.0Hz, 2H), 1.83 (s, 6H).

[0162] Compound 2e: white solid, yield 84%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.08 (d, J=7.6Hz, 1H), 7.01 (d, J=9.8Hz, 2H), 4.46 (s, 2H), 2.28 (d, J=9.1Hz, 6H), 1.75 (s, 6H).

[0163] Compound 2f: white solid, yield 79%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ 8.45 (d, J=4.0Hz, 1H), 7.83 (d, J=4.9Hz, 1H), 7.19 (dd, J=4.8, 4.8Hz, 1H), 1.79 (s, 6H).

[0164] Compound 2g: white solid, yield 81%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.62 (d, J=8.2Hz, 2H), 7.43 (d, J=8.2Hz, 2H), 1.83 (s, 6H).

[0165] Compound 2h: white solid, yield 83%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.72 (d, J=10.9Hz, 2H), 6.93 (d, J=10.9Hz, 2H), 3.87 (s, 3H), 1.82 (s, 6H).

[0166] Compound 2i: white solid, yield 74%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ7.62 (s, 1H), 7.54 (dd, J=14.2, 7.5Hz, 2H), 7.42-7.39 (m, 1H), 1.84 (s, 6H).

[0167] (2) Synthesis of compounds 3a to 3i

[0168] In a 100 mL eggplant-shaped bottle, 10 mmol of methyl 1-aminocyclobutanecarboxylate was dissolved in 20 mL of tetrahydrofuran, and 10 mmol of triethylamine was added. After stirring in an ice-water bath at 0°C for 10 min, 10 mmol of compounds 2a~2i were added respectively, and the ice bath was removed after stirring for 10 min. The mixture was heated to reflux at 110°C for 8 h, and the reaction was tracked by TLC spot plate detection. After the reaction of the raw materials was complete, the mixture was concentrated in vacuo to remove the solvent, and the residue was dissolved in 100 mL of ethyl acetate. The organic phase was washed once with 100 mL of 1 mol / L hydrochloric acid, 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated sodium chloride solution, and the organic phase was dried over sodium sulfate, filtered, and the organic phase was rotary evaporated to obtain a crude product. The crude product was purified by column chromatography (the volume ratio of ethyl acetate: petroleum ether was 3:1) to obtain a light yellow oily liquid, namely compounds 3a~3i.

[0169] Compound 3a: yellow solid, yield 72%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.39 (d, J=6.5Hz, 1H), 7.17 (d, J=6.0Hz, 1H), 7.05 (s, 1H), 6.80 (dd, J=36.4, 8.8Hz, 1H), 4.6 5 (d, J=93.3Hz, 2H), 3.76 (d, J=22.4Hz, 3H), 3.64 (s, 2H), 2.69-2.60 (m, 2H), 2.42-2.32 (m, 2H), 2.11-1.98 (m, 2H).

[0170] Compound 3b: yellow solid, yield 74%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CD3OD) δ8.16 (d, J=8.4Hz, 1H), 7.92 (d, J=8.4Hz, 1H), 7.82 (d, J=8.2Hz, 1H), 7.72 (d, J=8.4 Hz, 1H), 3.73 (s, 1H), 3.64 (s, 2H), 3.30 (s, 3H), 2.72-2.58 (m, 2H), 2.31-2.21 (m, 2H), 2.08-1.97 (m, 2H).

[0171] Compound 3c: yellow solid, yield 81%. The characterization data of the compound are as follows: 1H NMR (600MHz, CDCl3) δ7.71 (d, J=9.5Hz, 1H), 7.69 (s, 1H), 7.53-7.44 (m, 1H), 7.01 (t, J=7.6Hz, 1H), 6.96 (d, J =8.2Hz, 1H), 3.98 (s, 2H), 3.90 (s, 3H), 3.73 (s, 3H), 2.70-2.62 (m, 2H), 2.41-2.30 (m, 2H), 2.07-1.98 (m, 2H).

[0172] Compound 3d: yellow solid, yield 82%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.98 (d, J=8.9Hz, 2H), 7.71 (s, 1H), 7.40 (t, J=8.0Hz, 2H), 7.22 (t, J=7.5Hz, 1H), 7.07 (d, J=7. 9Hz, 2H), 7.00 (d, J = 8.9Hz, 2H), 3.90 (s, 2H), 3.71 (s, 3H), 2.70-2.64 (m, 2H), 2.38-2.32 (m, 2H), 2.08-2.02 (m, 2H).

[0173] Compound 3e: yellow solid, yield 74%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.48 (s, 1H), 7.07 (d, J = 7.6Hz, 1H), 7.00 (d, J = 9.7Hz, 1H), 6.93 (s, 1H), 3.78 (s, 2H), 3.73(s, 3H), 3.42(s, 2H), 2.68-2.60(m, 2H), 2.31-2.26(m, 5H), 2.19(s, 3H), 2.06-1.98(m, 2H).

[0174] Compound 3f: yellow solid, yield 81%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ7.82 (d, J=4.0Hz, 1H), 7.73 (d, J=5.0Hz, 1H), 7.71 (s, 1H), 7.16 (t, J=4 .3Hz, 1H), 3.89 (s, 2H), 3.71 (s, 3H), 2.70-2.63 (m, 2H), 2.38-2.31 (m, 2H), 2.08-1.99 (m, 2H).

[0175] Compound 3g: yellow solid, yield 85%. The characterization data of the compound are as follows: 1H NMR (600MHz, CDCl3) δ7.95 (d, J=8.5Hz, 2H), 7.53 (s, 1H), 7.46 (d, J=8.7Hz, 2H), 3 .92(s, 2H), 3.70(s, 3H), 2.72-2.62(m, 2H), 2.47-2.33(m, 2H), 2.10-2.01(m, 2H).

[0176] Compound 3h: yellow solid, yield 80%. The characterization data of the compound are as follows: 1 H NMR (600MHz, CDCl3) δ7.89 (d, J=8.1Hz, 2H), 7.74 (s, 1H), 7.28 (d, J=8.1Hz, 2H), 3.92 (s, 2H), 3.69(s, 3H), 2.72-2.60(m, 2H), 2.41(s, 3H), 2.38-2.30(m, 2H), 2.10-1.98(m, 2H).

[0177] Compound 3i: yellow solid, yield 79%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ7.96 (s, 1H), 7.87 (d, J=7.8Hz, 1H), 7.57 (d, J=8.1Hz, 1H), 7.53 (s, 1H), 7.43 (t, J= 7.9Hz, 1H), 3.92 (s, 1H), 3.74 (d, J=54.3Hz, 3H), 2.72-2.62 (m, 2H), 2.45-2.31 (m, 2H), 2.11-2.00 (m, 2H).

[0178] (3) Synthesis of compounds 4a to 4i

[0179] In a 100 mL eggplant-shaped bottle, 10 mmol of compound 3a-3i was dissolved in 20 mL of methanol, and sodium methoxide solution (30 mmol of sodium methoxide) was added. The reaction was heated to reflux at 80 °C for 8 h and monitored by TLC spot plate. After the reaction of the raw materials was complete, the methanol solution was removed by rotary evaporation, and the residue was dissolved in 30 mL of pure water. The pH was adjusted to 2 with 1 mol / L hydrochloric acid, and the mixture was extracted with hot ether at 25 °C. The organic phase was dried over sodium sulfate, filtered and evaporated to obtain a white solid, which was compound 4a-4i. The concentration of the sodium methoxide solution was 0.3 M, and the solvent was methanol.

[0180] The reaction formula for preparing the compounds 4a to 4i is as follows:

[0181]

[0182] Compound 4a: white solid, melting point 173-175°C, yield 83%. The characterization data of the compound are as follows: 1 HNMR (600MHz, dmso) δ9.54 (s, 1H), 7.59 (s, 1H), 7.38 (d, J=3.7Hz, 2H), 4.28 (s, 2H), 5.09 (s, 2H ), 2.26-2.21(m, 2H), 2.10-2.07(m, 2H), 1.91-1.80(m, 1H), 1.74-1.63(m, 1H).HRMS[ESI-]for C 15 H 13 Cl2NO4[(MH)-], m / z Calcd: 340.0119; Found: 340.0182.

[0183] Compound 4b: white solid, melting point 118-119°C, yield 87%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ8.31 (d, J=8.5Hz, 2H), 7.75 (d, J=8.7Hz, 2H), 6.34 (s, 1H), 2.55 -2.46(m, 2H), 2.59-2.53(m, 2H), 2.17-2.09(m, 1H), 1.86-1.8(m, 1H).HRMS[ESI-]forC 15 H 12 F3NO3.[(MH)-], m / z Calcd: 310.0730; Found: 311.0764.

[0184] Compound 4c: white solid, melting point 150-152°C, yield 82%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ7.52-7.42(m, 2H), 7.06-6.93(m, 2H), 6.55(s, 1H), 3.84(s, 3H), 2. 52-2.45(m, 2H), 2.27-2.20(m, 2H), 2.09-2.02(m, 1H), 1.83-1.74(m, 1H).HRMS[ESI-]forC 15 H 15 NO4[(MH)-], m / z Calcd: 272.0672; Found: 273.0991.

[0185] Compound 4d: white solid, melting point 161-162°C, yield 84%. The characterization data of the compound are as follows: 1HNMR (600MHz, CDCl3) δ8.33 (d, J=6.9Hz, 2H), 7.39 (t, J=7.0Hz, 2H), 7.20 (t, J=8.0Hz, 1H), 7.09 (d, J=8.7Hz, 2H), 7.03 (d , J=9.1Hz, 2H), 6.35(s, 1H), 2.58-2.54(m, 2H), 2.30-2.25(m, 2H), 2.16-2.08(m, 1H), 1.88-1.82(m, 1H).HRMS[ESI-]for C 20 H 17 NO4[(MH)-], m / zCalcd: 334.1076; Found: 335.1108.

[0186] Compound 4e: white solid, melting point 115-116°C, yield 79%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ7.11-7.04 (m, 2H), 6.99 (d, J=7.8Hz, 1H), 6.48 (s, 1H), 4.21 (d, J=29.8Hz, 2H), 2.61-2.52(m, 2H), 2.39-2.21(m, 8H), 2.18-2.06(m, 1H), 1.89-1.81(m, 1H).HRMS[ESI-]for C 17 H 19 NO3[(MH)-], m / z Calcd: 284.1196; Found: 285.1126.

[0187] Compound 4f: white solid, melting point 106-108°C, yield 86%. Characterization data of the compound are as follows: 1 HNMR (600MHz, dmso) δ9.64 (s, 1H), 9.20 (s, 1H), 8.14 (d, J = 4.8Hz, 1H), 7.33 (t, J = 4.5Hz, 1H), 2.3 7-2.32(m, 2H), 2.29-2.23(m, 2H), 1.97-1.89(m, 1H), 1.80(dq, J=9.1, 4.9Hz, 1H).HRMS[ESI-]for C 12 H 11 NO3S[(MH)-], m / z Calcd: 248.0381; Found: 249.0495.

[0188] Compound 4g: white solid, melting point 132-133°C, yield 81%. The characterization data of the compound are as follows: 1HNMR (600MHz, dmso) δ9.65 (s, 1H), 8.15 (d, J = 8.4Hz, 2H), 7.60 (d, J = 8.7Hz, 2H), 2.36- 2.31(m, 2H), 2.27-2.21(m, 2H), 1.93-1.87(m, 1H), 1.81-1.75(m, 1H).HRMS[ESI-]forC 14 H 12 ClNO3[(MH)-], m / z Calcd: 276.0425; Found: 277.0406.

[0189] Compound 4h: white solid, melting point 161-162°C, yield 79%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ8.39 (d, J=9.0Hz, 2H), 6.98 (d, J=9.1Hz, 2H), 6.43 (s, 1H), 3.88 (s, 3H) , 2.59-2.53(m, 2H), 2.30-2.23(m, 2H), 2.16-2.08(m, 1H), 1.89-1.80(m, 1H).HRMS[ESI-]for C 15 H 15 NO4[(MH)-], m / z Calcd: 272.0869; Found: 273.0957.

[0190] Compound 4i: white solid, melting point 141-142°C, yield 83%. The characterization data of the compound are as follows: 1 HNMR (600MHz, CDCl3) δ8.24 (s, 1H), 8.18 (d, J = 8.1Hz, 1H), 7.56 (d, J = 8.1Hz, 1H), 7.44 (t, J = 7.9Hz, 1H), 6.52(s, 1H), 2.61-2.55(m, 2H), 2.31-2.26(m, 2H), 2.17-2.11(m, 1H), 1.89-1.83(m, 1H).HRMS[ESI-]for C 14 H 12 ClNO3[(MH)-], m / z Calcd: 276.0413; Found: 278.0406.

[0191] (ii) When n=3 and R1 is 2,4-dichlorophenoxymethyl (i.e., substituent Ia), the compound 6a represented by formula I is prepared by the following method, the steps are as follows:

[0192] (1) Synthesis of compound 5a

[0193] In a 100 mL eggplant-shaped bottle, 10 mmol of methyl 1-aminocyclopentanecarboxylate was dissolved in 30 mL of 1,4-dioxane, and 10 mmol of triethylamine was added. After stirring in an ice-water bath at 0°C for 10 min, 10 mmol of compound 2a was added and stirred for 10 min, and then the ice bath was removed. The mixture was heated to reflux at 100°C for 8 h, and the reaction was tracked by TLC spot plate detection. After the reaction of the raw material was complete, it was concentrated in vacuo to remove the solvent, and the residue was dissolved in 100 mL of ethyl acetate. The organic phase was washed once with 100 mL of 1 mol / L hydrochloric acid (80-100 mL), 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated sodium chloride solution, and the organic phase was dried over sodium sulfate, filtered, and the organic phase was rotary evaporated to obtain a crude product. The crude product was purified by column chromatography (the volume ratio of ethyl acetate to petroleum ether was 3:1) to obtain a light yellow oily liquid, namely compound 5a.

[0194] Compound 5a: yellow solid, yield 82%. The characterization data of the compound are as follows: 1 H NMR (600MHz, dmso) δ8.57 (s, 1H), 7.90 (d, J = 9.4Hz, 1H), 7.82 (d, J = 7.5Hz, 2H), 7.52-7.45 (m, 2H), 7.44 (q, J = 7.0Hz, 1H), 7.32 ( d, J=7.5Hz, 1H), 5.72 (s, 1H), 4.32 (s, 2H), 3.56 (s, 3H), 3.44 (s, 2H), 2.10-2.02 (m, 2H), 1.91-1.83 (m, 2H), 1.70-1.59 (m, 4H).

[0195] (2) Synthesis of Compound 6a

[0196] In a 100 mL eggplant-shaped bottle, 10 mmol of compound 5a was dissolved in 30 mL of methanol, and sodium methoxide solution (30 mmol of sodium methoxide) was added. The reaction was heated to reflux at 80 °C for 8 h and monitored by TLC spot plate. After the reaction of the raw materials was complete, the methanol solution was removed by rotary evaporation, and the residue was dissolved in 30 mL of pure water. The pH was adjusted to 2 with 1 mol / L hydrochloric acid, and the mixture was extracted with hot ether at 25 °C. The organic phase was dried over sodium sulfate, filtered and evaporated to obtain a white solid, which was compound 6a. The concentration of the sodium methoxide solution was 0.3 M, and the solvent was methanol.

[0197] The reaction formula for preparing the compound 6a is shown below:

[0198]

[0199] Compound 6a: white solid, melting point 173-174°C, yield 76%. The characterization data of the compound are as follows: 1 HNMR (600MHz, dmso) δ9.43 (s, 1H), 8.01 (d, J=5.0Hz, 1H), 7.92 (t, J=9.7Hz, 1H), 7.83 (d, J=7.8Hz, 1H), 7.50 (t, J=9. 5Hz, 2H), 7.48-7.42(m, 2H), 4.59(s, 2H), 1.98-1.90(m, 2H), 1.79-1.673(m, 4H), 1.71-1.64(m, 2H).HRMS[ESI-]for C 16 H 15 Cl2NO4[(MH)-], m / z Calcd: 355.0369; Found: 357.0129.

[0200] Example 2

[0201] The preparation method of the compound shown in formula II is as follows:

[0202] (I) When n=1 or 3, and R2 is a substituent IIa, the compounds represented by formula II are 8a and 8b, and the following preparation methods are used to prepare compounds 8a and 8b, respectively. The steps are as follows:

[0203] (1) Synthesis of compounds 7a and 7b

[0204] In a 100 mL eggplant-shaped bottle, 10 mmol of 1-aminocyclopropanecarboxylic acid methyl ester and 1-aminocyclopentanecarboxylic acid methyl ester were taken and dissolved in 40 mL of dichloromethane, respectively. 20 mmol of 4-dimethylaminopyridine and 20 mmol of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride were added, respectively. After stirring at room temperature (25°C) for 10 min, 20 mmol of 2,4-dichlorophenylacetic acid was added, and the reaction was stirred for 10 h. After TLC tracking of the raw material until the reaction was complete, excess salt was removed by suction filtration. The dichloromethane phase was washed 3 times with 40 mL of 5% sodium bicarbonate solution, and then washed 3 times with 40 mL of pure water until the solution was neutral. The dichloromethane phase was then dried over sodium sulfate, filtered, and the organic phase was rotary evaporated to obtain a crude product. The crude product was purified by column chromatography (the volume ratio of ethyl acetate to petroleum ether was 4:1) to obtain a white solid, namely, compounds 7a and 7b.

[0205] Compound 7a: white solid, melting point 117-119°C, yield 94%. The characterization data of the compound are as follows: 1HNMR (600MHz, DMSO-d6) δ: 8.76 (s, 1H), 7.56 (d, J=1.1Hz, 1H), 7.44-7.36 (m, 2H), 3.58 (s, 3H), 3.56 (s, 2H), 1.40-1.34 (m, 2H), and 1.08-0.98(m,2H).HRMS[ESI+]for C 13 H 13 Cl2NO3[(M+H)+], m / z Calcd: 302.0345; Found: 302.0341.

[0206] Compound 7b: white solid, melting point 111-115°C, yield 95%. The characterization data of the compound are as follows: 1 HNMR (600MHz, DMSO-d6) δ: 8.56 (s, 1H), 7.56 (s, 1H), 7.46-7.30 (m, 2H), 3.57 (s, 2H), 3.55 (s, 3H), 2.07-2.00 (m, 2H), 1.91-1.85 (m, 2H), and 1.71-1.59(m,4H).HRMS[ESI+]forC 15 H 17 Cl2NO3[(M+H)+], m / z Calcd: 330.0658; Found: 330.0661.

[0207] (2) Synthesis of compounds 8a and 8b

[0208] In a 100 mL eggplant-shaped bottle, 10 mmol of compounds 7a and 7b were dissolved in 30 mL of methanol respectively, stirred for 5 min, sodium methoxide solution (30 mmol of sodium methoxide) was added, and the reaction was heated to reflux at 80 °C for 8 h. TLC spot plate monitoring and tracking was performed. After the raw material reaction was complete, the methanol solution was removed by rotary evaporation, and the residue was dissolved in 30 mL of pure water. The pH was adjusted to 2 with 1 mol / L hydrochloric acid, and extracted with 25 °C hot ether. The organic phase was placed on sodium sulfate and dried. The organic phase was filtered and evaporated to obtain a white solid, which was compounds 8a and 8b; wherein the concentration of the sodium methoxide solution was 0.3 M, and the solvent was methanol.

[0209] The reaction formula for preparing the compounds 8a and 8b is as follows:

[0210]

[0211] Compound 8a: white solid, melting point 103-105°C, yield 92%. The characterization data of the compound are as follows: 1HNMR (600MHz, DMSO-d6) δ: 11.09 (s, 1H), 7.70 (s, 1H), 7.60 (d, J=2.1Hz, 1H), 7.40 (dd, J=8.4, 2.2Hz, 1H), 7.30 (d, J=8.3Hz, 1H), 1.31-1.28 (m, 2H), and 1.24-1.21(m,2H).HRMS[ESI+]for C 12 H9Cl2NO2[(M+H)+], m / z Calcd: 270.0083; Found: 270.0085.

[0212] Compound 8b: white solid, melting point 106-109°C, yield 92%. The characterization data of the compound are as follows: 1 HNMR (600MHz, DMSO-d6) δ: 11.14 (s, 1H), 7.94 (s, 1H), 7.59 (d, J=2.1Hz, 1H), 7.38 (dd , J=8.3, 2.1Hz, 1H), 7.26 (d, J=8.3Hz, 1H), 2.09-2.03 (m, 2H), 1.82-1.72 (m, 4H), and 1.62-1.58(m,2H).HRMS[ESI+]for C 14 H 13 Cl2NO2[(M+H)+], m / z Calcd: 298.0396; Found: 298.0395.

[0213] (ii) When n=3, R2 is a substituent IIb-f, the compound represented by formula II is compound 9a, compound 9b, compound 9c, compound 9d and compound 9e, and the following preparation methods are used to prepare compounds 9a to 9e, respectively, in the following steps:

[0214] In a 100 mL eggplant-shaped bottle, 15 mmol of benzoic acid, 4-trifluoromethylbenzoic acid, n-valeric acid, isovaleric acid and 3,4-difluorobenzoic acid, 15 mmol of 4-dimethylaminopyridine and 15 mmol of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride were dissolved in 20-30 mL of dichloromethane respectively. After stirring at room temperature for 30 min at 25 °C, 10 mmol of 8b was added to the mixed solution. The mixture was reacted at room temperature for 10 h at 25 °C and followed by TLC until the reaction of the raw materials was complete. After the reaction was completed, the mixture was filtered and the filtrate was diluted with 30 mL of dichloromethane. The organic phase was washed three times with 5% NaHCO3 solution (50 mL each time), 1 mol / L hydrochloric acid (50 mL each time) and pure water (50 mL each time). The dichloromethane phase was then dried over sodium sulfate and concentrated. A white solid was obtained by column chromatography (the volume ratio of ethyl acetate to petroleum ether was 3:1), which was compounds 9a to 9e.

[0215] The reaction formula for preparing the compounds 9a to 9e is as follows:

[0216]

[0217] Compound 9a: white solid, melting point 141-144°C, yield 82%. The characterization data of the compound are as follows: 1 HNMR (600MHz, dmso) δ8.91 (s, 1H), 8.19 (d, J = 8.4Hz, 2H), 7.92 (d, J = 8.5Hz, 2H), 7.57 (s, 1H), 7.42 (d, J = 8 .5Hz, 1H), 7.38(d, J=8.4Hz, 1H), 2.17-2.09(m, 2H), 1.88-1.83(m, 2H), 1.78-1.71(m, 4H).HRMS[ESI-]for C 22 H 16 Cl2F3NO3[(MH)-], m / z Calcd: 469.0435; Found: 471.0498.

[0218] Compound 9b: white solid, melting point 132-133°C, yield 80%. The characterization data of the compound are as follows: 1 HNMR(600MHz,dmso)δ8.85(s,1H),7.98(d,J=8.5Hz,2H),7.72(t,J=7.4Hz,1H),7.58-7.53(m,3H),7.41(d,J =8.4Hz,1H),7.36(d,J=8.4Hz,1H),2.14-2.07(m,2H),1.87-1.82(m,2H),1.78-1.72(m,4H).HRMS[ESI-]for C21 H 17 Cl2NO3[(MH)-], m / z Calcd: 401.0561; Found: 403.0625.

[0219] Compound 9c: white solid, melting point 112-114°C, yield 81%. The characterization data of the compound are as follows: 1 HNMR(600MHz,dmso)δ8.73(s,1H),7.61(d,J=2.2Hz,1H),7.42(dd,J=8.4,2.2Hz,1H),7.26(d,J=8.4Hz,1H),2.45(t,J=7.2Hz,2H),1 .98-1.93(m,2H),1.85-1.80(m,2H),1.73-1.65(m,4H),1.42-1.37(m,2H),1.11-1.05(m,2H),0.76(t,J=7.4Hz,3H).HRMS[ESI-]forC 19 H 21 Cl2NO3[(MH)-], m / z Calcd: 381.0874; Found: 383.0938.

[0220] Compound 9d: white solid, melting point 125-126°C, yield 77%. The characterization data of the compound are as follows: 1 HNMR(600MHz,dmso)δ8.73(s,1H),7.61(s,1H),7.42(d,J=10.3Hz,1H),7.26(d,J=8.4Hz,1H),2.35(d,J=7 .2Hz,2H),1.98-1.92(m,2H),1.89-1.80(m,3H),1.73-1.66(m,4H),0.75(d,J=7.2Hz,6H).HRMS[ESI-]for C 19 H 21 Cl2NO3[(MH)-], m / z Calcd: 381.0874; Found: 383.0938.

[0221] Compound 9e: white solid, melting point 134-135°C, yield 82%. The characterization data of the compound are as follows: 1HNMR(600MHz,dmso)δ8.88(s,1H),8.04(t,J=9.5Hz,1H),7.89(s,1H),7.62(q,J=8.1Hz,1H),7.57(s,1H ),7.42(d,J=10.6Hz,1H),7.37(d,J=8.2Hz,1H),2.13(s,2H),1.85(s,2H),1.73(s,4H).HRMS[ESI-]for C 21 H 15 Cl2F2NO3[(MH)-], m / z Calcd: 437.0373; Found: 439.0436.

[0222] The hydrogen spectrum structure of compound 9b is shown in Figure 1 As shown; the hydrogen spectrum structure of compound 9d is shown Figure 2 shown.

[0223] In vitro inhibition evaluation of the spirocyclic tert-amino acid compounds prepared in Examples 1 and 2 on some cancer cells

[0224] The test cancer cell numbers: NCI-H1299 human large cell lung cancer (LCC) cells (cell number: PWE-HU058, purchased from Shanghai Saiyi Biotechnology Co., Ltd.), RKO human colon adenocarcinoma cells (cell number: PWE-HU112, purchased from Shanghai Saiyi Biotechnology Co., Ltd.), MCF-7 human breast cancer cells (cell number: PWE-HU005, purchased from Shanghai Saiyi Biotechnology Co., Ltd.).

[0225] Operation process:

[0226] 1. Cultivate the purchased cells, take out the cells when the number of cells is sufficient and the cells are in good condition, and prepare cell suspension after trypsin digestion. Count the cell suspension using a hemocytometer and adjust the cell concentration to 2.5×10 4 / mL. The cell suspension was then inoculated on a 96-well culture plate (200 μL / well), 199 μL of the prepared cell suspension was added to each well, and the cells were cultured in an incubator with saturated humidity, 5% CO2 and 37°C for 24 hours before the drug was added. 1 μL of the prepared drug solution was added to each well, so that the final drug concentrations in the cell culture medium were 0.0025 mg / mL, 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, 0.04 mg / mL, 0.08 mg / mL, 0.16 mg / mL and 0.32 mg / mL (three replicate wells were set in parallel for each concentration), and two control groups were set up, namely the DMSO control group and the untreated group.

[0227] 2. Place the inoculated cell wells in the incubator and culture for 20 hours, then add 20 μL of 5 mg / mL MTT solution. After incubation for 4 hours, carefully aspirate the old culture medium, then add 200 μL of DMSO to dissolve the crystals, and place the 96-well plate on a shaker in the dark for 10 minutes.

[0228] 3. Place the 96-well plate in the microplate reader, set the parameters and start measuring the absorbance (A) at 490 nm to obtain the OD values ​​of H1299, RKO and MCF-7 cells treated with different drug concentrations. Based on the obtained data, the inhibition rate and IC of the drug were calculated by SPSS software. 50 value.

[0229] The inhibition rate was calculated as follows: cell growth inhibition rate (IR) = (1-AS / A0) × 100%, where AS is the absorbance value of the treatment group and A0 is the absorbance value of the control group.

[0230] Experimental results: The inhibitory activity of each compound on cancer cells is shown in Tables 1 to 3 below.

[0231] Table 1 Determination of the inhibition rate of target compounds on H1299 cancer cells for 24 hours

[0232]

[0233]

[0234] Table 2 Determination of the inhibition rate of target compounds on RKO cancer cells at 24h

[0235]

[0236] Table 3 IC values ​​of some target compounds against various cancer cells at 24h 50 value

[0237]

[0238] Note: H1299 refers to human large cell lung cancer (LCC) cells, RKO refers to human colon adenocarcinoma cells, and MCF-7 refers to human breast cancer cells.

[0239] As shown in Tables 1 and 2, spirocyclic amino acid compounds have inhibitory effects on H1299 and RKO cancer cells, and the inhibitory effects vary due to different functional groups. In the experiment of H1299 cancer cells, when the concentration is 1 mg / mL, compound 9e has the strongest inhibitory effect, with an inhibition rate of 83.6%. Compounds 9d, 4i, and 4h also have strong inhibitory effects on H1299 cancer cells, with inhibition rates of 80.3%, 78.6%, and 75.6%, respectively. When the concentration is 0.01 mg / mL, compound 9e still has the strongest inhibitory effect on H1299 cancer cells, with an inhibition rate of 47.8%. Compound 9d also has a strong inhibitory effect on H1299 cancer cells, with an inhibition rate of 40.2%. In the experiment on RKO cancer cells, compound 9d had the strongest inhibitory effect at a concentration of 1 mg / mL, with an inhibition rate of 100%. Compounds 9b, 9e and 9c also showed strong inhibitory effects, with inhibition rates of 88.6%, 82.4% and 81.3%, respectively. When the concentration was 0.01 mg / mL, compound 9d still had the strongest inhibitory effect on H1299 cancer cells, with an inhibition rate of 53.2%. Compounds 9e, 9b and 9c also showed strong inhibitory effects, with inhibition rates of 47.6%, 46.5% and 43.3%, respectively.

[0240] As shown in Table 3, for H1299 cancer cells, the IC 50 The smallest value was 0.022 mg / mL, followed by compound 9d at 0.051 mg / mL. For RKO cancer cells, the IC 50 The smallest value was 0.009 mg / mL, followed by compound 9b at 0.015 mg / mL. The IC value of compound 9c for MCF-7 cancer cells was 50 The smallest value was 0.035 mg / mL, followed by compound 9b at 0.175 mg / mL.

[0241] In summary, the inhibitory effects of the compounds of formula II (8a-9e) on H1299, RKO and MCF-7 cancer cells are stronger than those of the compounds of formula I (4a-6a), and the effects of compounds 9d and 9b are the best.

[0242] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A spirocyclic amino acid compound, wherein the spirocyclic amino acid compound is any one of the following: .

2. The method for preparing the spirocyclic amino acid compound according to claim 1, comprising the following steps: 1) mixing 1-aminocyclopentanecarboxylic acid methyl ester, a solvent, a catalyst and 2,4-dichlorophenylacetic acid to carry out an amidation reaction to obtain a third intermediate; 2) mixing the third intermediate obtained in step 1), a solvent and a catalyst, and performing a Diekmann condensation reaction to obtain a fourth intermediate; mixing the fourth intermediate, an acid, a catalyst and a solvent, and performing an esterification reaction to obtain a spirocyclic tertamine acid compound; The acid is benzoic acid, 4-trifluoromethylbenzoic acid, n-valeric acid, isovaleric acid or 3,4-difluorobenzoic acid; The structural formula of the third intermediate is , n=3; The structural formula of the fourth intermediate is .

3. The preparation method according to claim 2, characterized in that: The temperature of the esterification reaction in step 2) is 10-30° C., and the time of the esterification reaction is 8-10 hours.

4. Use of the spirocyclic tert-amino acid compound according to claim 1 in the preparation of anticancer drugs.

5. The use according to claim 4, characterized in that: The cancer cells in the anticancer drug are human large cell lung cancer cells, human colon adenocarcinoma cells and human breast cancer cells.